Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000902664-25-002308·Caligan Partners LP
Schedule 13G ownership disclosure
Y-MABS THERAPEUTICS INC
Common stock, $0.0001 par value per share · CUSIP: 984241109
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Caligan Partners LP
Shares: 2,342,609.00 · Class: 5.2%
- David Johnson
Shares: 2,342,609.00 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-002308
- Form type
- SCHEDULE 13G
- Filer
- Caligan Partners LP
- CIK
- CIK 1727492
- Filed
- May 14, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership